Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in stage 1 of NSCLC phase II combination trial with KEYTRUDA®

· Clinical response merits initiation of stage 2 of the Phase II combination trial · 24 patients treated to date, 48 patients to be treated in total · Responses will be correlated with AXL and PD-L1 biomarkersBergen, Norway, June 26, 2018 – BerGenBio ASA (OSE:BGBIO) announces today that on a top-line, preliminary basis, the first efficacy endpoint has been met in its Phase II clinical trial (BGBC008) evaluating bemcentinib, a first-in-class oral selective AXL inhibitor, in combination with the Merck & Co., Inc., Kenilworth, N.J., USA[1]